Predicting risks and outcomes of advanced overactive bladder treatments for older adults
Risk determination and prognostication for older and frail older adults undergoing advanced treatments for overactive bladder
This project will build a tool to predict which third-line treatments for overactive bladder are likely to help or harm older and frail adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11303414 on NIH RePORTER |
What this research studies
Younger and middle-aged adults have been well-studied for third-line overactive bladder treatments like onabotulinumtoxinA, PTNS, and sacral neuromodulation, but outcomes in older and frail adults are poorly understood. The team will examine who receives these procedures, what complications and benefits occur, and whether use differs by age, frailty, race, socioeconomic status, or provider experience. They will analyze clinical and procedure data to link frailty and other factors with outcomes. The final goal is an individualized, actionable prognostic tool to help patients and clinicians make safer treatment choices.
Who could benefit from this research
Good fit: Ideal candidates are adults aged 65 and older, especially those who are frail and are considering or have had third-line treatments for refractory overactive bladder (onabotulinumtoxinA, PTNS, or sacral neuromodulation).
Not a fit: Patients who are young, not frail, or who have mild overactive bladder managed without third-line procedures are unlikely to directly benefit from this specific prognostic tool.
Why it matters
Potential benefit: If successful, this work could help older adults and their doctors choose safer, more effective overactive bladder treatments based on frailty and personal risk.
How similar studies have performed: Previous research has measured outcomes of these procedures in younger, healthier adults, but applying frailty-focused prognostic tools to older adults is largely novel.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Suskind, Anne M. — University of California, San Francisco
- Study coordinator: Suskind, Anne M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.